BRPI0415226A - regime de tratamento de cáncer de mama - Google Patents

regime de tratamento de cáncer de mama

Info

Publication number
BRPI0415226A
BRPI0415226A BRPI0415226-3A BRPI0415226A BRPI0415226A BR PI0415226 A BRPI0415226 A BR PI0415226A BR PI0415226 A BRPI0415226 A BR PI0415226A BR PI0415226 A BRPI0415226 A BR PI0415226A
Authority
BR
Brazil
Prior art keywords
breast cancer
treatment regimen
cancer treatment
treatment
therapy
Prior art date
Application number
BRPI0415226-3A
Other languages
English (en)
Inventor
Paul E Goss
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of BRPI0415226A publication Critical patent/BRPI0415226A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/32—Antioestrogens

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

"REGIME DE TRATAMENTO DE CáNCER DE MAMA". A presente invenção refere-se a um regime de tratamento para o tratamento de câncer de mama em que a terapia de antagonista de estrogênio (antiestrogênio) é seguida por terapia com um agente de depleção de estrogênio antes da progressão da doença.
BRPI0415226-3A 2003-10-09 2004-10-08 regime de tratamento de cáncer de mama BRPI0415226A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US10/681,913 US20050080062A1 (en) 2003-10-09 2003-10-09 Breast cancer treatment regimen
PCT/EP2004/011303 WO2005037263A1 (en) 2003-10-09 2004-10-08 Breast cancer treatment regimen

Publications (1)

Publication Number Publication Date
BRPI0415226A true BRPI0415226A (pt) 2006-12-05

Family

ID=34422388

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415226-3A BRPI0415226A (pt) 2003-10-09 2004-10-08 regime de tratamento de cáncer de mama

Country Status (9)

Country Link
US (1) US20050080062A1 (pt)
EP (1) EP1673076A1 (pt)
JP (1) JP2007508265A (pt)
CN (1) CN101404988A (pt)
AU (1) AU2004281527A1 (pt)
BR (1) BRPI0415226A (pt)
CA (1) CA2541264A1 (pt)
MX (1) MXPA06003928A (pt)
WO (1) WO2005037263A1 (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007045027A1 (en) 2005-10-19 2007-04-26 Chavah Pty Ltd Reduction of side effects from aromatase inhibitors used for treating breast cancer
US9351977B2 (en) 2014-10-22 2016-05-31 Chavah Pty Ltd. Methods of reducing mammographic breast density and/or breast cancer risk
SG11201803260PA (en) 2015-10-22 2018-05-30 Havah Therapeutics Pty Ltd Methods of reducing mammographic breast density and/or breast cancer risk
AU2020287392A1 (en) 2019-06-03 2021-12-23 Havah Therapeutics Pty Ltd Pharmaceutical formulations and systems for delivery of an androgenic agent and an aromatase inhibitor and methods for use

Also Published As

Publication number Publication date
US20050080062A1 (en) 2005-04-14
MXPA06003928A (es) 2006-07-05
CA2541264A1 (en) 2005-04-28
CN101404988A (zh) 2009-04-08
JP2007508265A (ja) 2007-04-05
AU2004281527A1 (en) 2005-04-28
EP1673076A1 (en) 2006-06-28
WO2005037263A1 (en) 2005-04-28

Similar Documents

Publication Publication Date Title
BRPI0511967A (pt) usos de derivados de 5-amino-2,4,7-trioxo-3,4,7,8-tetrahidro-2h-pirido[2,3-d] pirimidina e compostos relacionados para o tratamento de cáncer, suas composições farmacêuticas, embalagens comerciais e respectivo kit
IL177645A0 (en) Phospholipid analogs for diagnosis and treatment of cancer
DOP2010000141A (es) Tratamiento de cancer de mama con un inhibidor de parp solo o en combinacion con agentes anti-tumorales
BRPI0507544A (pt) combinação de agonistas de benzotiazol-2-ona beta-2 adrenoreceptores e corticosteróides para o tratamento de doenças respiratórias
DOP2012000290A (es) 4-yodo-3-nitrobenzamida en combinacion con agentes anti-tumorales para el uso en el tratamiento de cancer utero y cancer de ovario
BR0309355A (pt) 2-(2,6-diclorofenil)-diarilimidazóis
ECSP045474A (es) 1-(aminoalquil)-3-sulfonilazaindoles como ligandos de 5-hidroxitriptamina-6
BR112012012610A2 (pt) terapia de combinação para o tratamento de câncer e ensaios diagnósticos para o uso na mesma
DOP2006000057A (es) Composición farmaceútica para el tratamiento del cáncer
CY1110889T1 (el) C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους
ECSP055911A (es) Compuestos tricíclicos inhibidores de proteína quinasa para mejorar la eficacia de agentes antineoplásicos y terapia de radiación
AR088110A2 (es) Uso de un inmunoconjugado que comprende un anticuerpo anti-erbb2 para la manufactura de un medicamento
BRPI0612845A8 (pt) composto, formulação farmacêutica, métodos para tratar câncer e para sintetizar um composto de fórmula alq-dispasador
UY27793A1 (es) Pirazolopiridinas substituidas con carbamato
BRPI0507684B8 (pt) agentes de contraste para imagem de perfusão miocárdica
IS2517B (is) Notkun á setnum 2-amínótetralínum í fyrirbyggjandi meðferð á Parkinsons-veiki
BR0308429A (pt) Aroilpiridinonas monocìclicas como agentes antiinflamatórios
SV2002000357A (es) Acidos malonamicos y derivados de los mismos como ligandos de receptor tiroideo ref pc10748amag/bb
UY28945A1 (es) Derivados de pirrolopiridina
BR112015022820A8 (pt) ensaio para selecionar um regime de tratamento para um indivíduo com depressão, uso de um composto compreendendo folato, composição e kit
UY26456A1 (es) Compuestos que fijan la estructura g-cuadruplex de los telomeros, triazinas de aplicación de dichos compuestos, la utilización de dichos compuestos como productos farmacéuticos y las asociaciones terapéuticas que los incluyen.
BRPI0408063A (pt) métodos e composições envolvendo mda-7
BR0207316A (pt) Derivados de epotilona para o tratamento de tumores refratários
UY28839A1 (es) Agentes terapeuticos
BRPI0411451A (pt) formas de dosagens orais de memantina

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal acc. article 33 of ipl - extension of time limit for request of examination expired